Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung.

Conclusions: Although saracatinib was well tolerated in this patient population, there was no apparent impact of the drug in this double-blinded, placebo-controlled trial on OS, and Src inhibition alone may not be sufficient to suppress metastatic progression in osteosarcoma. There is a suggestion of potential clinical benefit as evidenced by longer PFS in patients randomized to saracatinib based on limited numbers of patients treated. PMID: 32398945 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/32398945?dopt=Abstract

Source: Sarcoma - May 15, 2020 Category: Cancer & Oncology Tags: Sarcoma Source Type: research